Bisphosphonates for cardiovascular risk reduction: A systematic review and meta-analysis

Atherosclerosis

Volumn 252, Issue , 2016, Pages 106-115

  Kranenburg, Guido ^a   Bartstra, Jonas W ^a   Weijmans, Maaike ^a   de Jong, Pim A ^a   Mali, Willem P ^a   Verhaar, Harald J ^a   Visseren, Frank L J ^a   Spiering, Wilko ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Arterial calcification; Arterial stiffness; Atherosclerosis; Bisphosphonates; cardiovascular events; Cardiovascular mortality; Mortality

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID;

ARTERIAL STIFFNESS; ARTERY CALCIFICATION; ARTERY WALL; ARTICLE; ATHEROSCLEROSIS; CANCER PATIENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COCHRANE LIBRARY; CONFIDENCE INTERVAL; DRUG EFFECT; EMBASE; HUMAN; MEDLINE; META ANALYSIS; MORTALITY; OSTEOPOROSIS; OUTCOME ASSESSMENT; POPULATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; RISK REDUCTION; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; ARTERY; CALCINOSIS; CARDIOVASCULAR SYSTEM; COMPLICATION; DRUG EFFECTS; FEMALE; MALE; NEOPLASM; PATHOPHYSIOLOGY;

ARTERIES; CALCINOSIS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; DIPHOSPHONATES; FEMALE; HUMANS; MALE; NEOPLASMS; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; RISK REDUCTION BEHAVIOR; VASCULAR STIFFNESS;

EID: 84982815702     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.06.039     Document Type: Article

References (98)

1. [1] Mozaffarian, D., Benjamin, E.J., Go, A.S., Arnett, D.K., Blaha, M.J., Cushman, M., de Ferranti, S., Despres, J., Fullerton, H.J., Howard, V.J., et al. Heart disease and stroke Statistics-2015 update: a report from the American heart association. Circulation 131:4 (2015), 29–322.
2. [2] Rennenberg, R.J., Kessels, A.G., Schurgers, L.J., van Engelshoven, J.M., de Leeuw, P.W., Kroon, A.A., Vascular calcifications as a marker of increased cardiovascular risk: a meta-analysis. Vasc. Health Risk Manag. 5:1 (2009), 185–197.
3. [3] Lanzer, P., Boehm, M., Sorribas, V., Thiriet, M., Janzen, J., Zeller, T., St Hilaire, C., Shanahan, C., Medial vascular calcification revisited: review and perspectives. Eur. Heart J. 35:23 (2014), 1515–1525.
4. [4] von der Recke, P., Hansen, M.A., Hassager, C., The association between low bone mass at the menopause and cardiovascular mortality. Am. J. Med. 106:3 (1999), 273–278.
5. [5] Tanko, L.B., Bagger, Y.Z., Christiansen, C., Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women. Calcif. Tissue Int. 73:1 (2003), 15–20.
6. [6] Montalcini, T., Emanuele, V., Ceravolo, R., Gorgone, G., Sesti, G., Perticone, F., Pujia, A., Relation of low bone mineral density and carotid atherosclerosis in postmenopausal women. Am. J. Cardiol. 94:2 (2004), 266–269.
7. [7] Vogt, M.T., Cauley, J.A., Kuller, L.H., Nevitt, M.C., Bone mineral density and blood flow to the lower extremities: the study of osteoporotic fractures. J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 12:2 (1997), 283–289.
8. [8] van der Klift, M., Pols, H.A., Hak, A.E., Witteman, J.C., Hofman, A., de Laet, C.E., Bone mineral density and the risk of peripheral arterial disease: the Rotterdam Study. Calcif. Tissue Int. 70:6 (2002), 443–449.
9. [9] Thompson, B., Towler, D.A., Arterial calcification and bone physiology: role of the bone-vascular axis. Nat. Rev. Endocrinol. 8:9 (2012), 529–543.
10. [10] Evrard, S., Delanaye, P., Kamel, S., Cristol, J.P., Cavalier, E., Vascular calcification: from pathophysiology to biomarkers. Clin. Chim. Acta; Int. J. Clin. Chem. 438 (2015), 401–414.
11. [11] Fleisch, H., Schibler, D., Maerki, J., Frossard, I., Inhibition of aortic calcification by means of pyrophosphate and polyphosphates. Nature 207:5003 (1965), 1300–1301.
12. [12] Lomashvili, K.A., Narisawa, S., Millan, J.L., O'Neill, W.C., Vascular calcification is dependent on plasma levels of pyrophosphate. Kidney Int. 85:6 (2014), 1351–1356.
13. [13] Bevilacqua, M., Dominguez, L.J., Rosini, S., Barbagallo, M., Bisphosphonates and atherosclerosis: why?. Lupus 14:9 (2005), 773–779.
14. [14] Elmariah, S., Delaney, J.A., O'Brien, K.D., Budoff, M.J., Vogel-Claussen, J., Fuster, V., Kronmal, R.A., Halperin, J.L., Bisphosphonate use and prevalence of valvular and vascular calcification in women MESA (the multi-ethnic study of atherosclerosis). J. Am. Coll. Cardiol. 56:21 (2010), 1752–1759.
15. [15] Schenk, R., Merz, W.A., Muhlbauer, R., Russell, R.G., Fleisch, H., Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl 2 MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcif. Tissue Res. 11:3 (1973), 196–214.
16. [16] Santos, L.L., Cavalcanti, T.B., Bandeira, F.A., Vascular effects of bisphosphonates-a systematic review. Clin. Med. Insights: Endocrinol. Diabetes 5 (2012), 47–54.
17. [17] Vestergaard, P., Acute myocardial infarction and atherosclerosis of the coronary arteries in patients treated with drugs against osteoporosis: calcium in the vessels and not the bones?. Calcif. Tissue Int. 90:1 (2012), 22–29.
18. [18] Lyles, K.W., Colon-Emeric, C.S., Magaziner, J.S., Adachi, J.D., Pieper, C.F., Mautalen, C., Hyldstrup, L., Recknor, C., Nordsletten, L., Moore, K.A., et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N. Engl. J. Med. 357:18 (2007), 1799–1809.
19. [19] Black, D.M., Delmas, P.D., Eastell, R., Reid, I.R., Boonen, S., Cauley, J.A., Cosman, F., Lakatos, P., Leung, P.C., Man, Z., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. 356:18 (2007), 1809–1822.
20. [20] Higgins, J.P.T., Altman, D.G., Gøtzsche, P.C., Jüni, P., Moher, D., Oxman, A.D., Savović, J., Schulz, K.F., Weeks, L., Sterne, J.A.C., The Cochrane Collaboration's tool for assessing risk of bias in randomised trials., 343, 2011.
21. [21] DerSimonian, R., Laird, N., Meta-analysis in clinical trials. Control. Clin. Trials 7:3 (1986), 177–188.
22. [22] Moher, D., Cook, D.J., Eastwood, S., Olkin, I., Rennie, D., Stroup, D.F., Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet, 354(9193), 1896-1900.
23. [23] Belch, A.R., Bergsagel, D.E., Wilson, K., O'Reilly, S., Wilson, J., Sutton, D., Pater, J.L., Johnston, D., Zee, B., Effect of daily etidronate on the osteolysis of multiple myeloma. J. Clin. Oncol. 9:8 (1991), 1397–1402.
24. [24] van Holten-Verzantvoort, A.T., Kroon, H.M., Bijvoet, O.L., Cleton, F.J., Beex, L.V., Blijham, G., Hermans, J., Neijt, J.P., Papapoulos, S.E., Sleeboom, H.P., et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 11:3 (1993), 491–498.
25. [25] Kanis, J.A., Powles, T., Paterson, A.H.G., McCloskey, E.V., Ashley, S., Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 19:6 (1996), 663–667.
26. [26] Berenson, J.R., The efficacy of pamidronate disodium in the treatment of osteolytic lesions and bone pain in multiple myeloma. Rev. Contemp. Pharmacother. 9:3 (1998), 195–203.
27. [27] Hortobagyi, G.N., Theriault, R.L., Lipton, A., Porter, L., Blayney, D., Sinoff, C., Wheeler, H., Simeone, J.F., Seaman, J.J., Knight, R.D., et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J. Clin. Oncol. 16:6 (1998), 2038–2044.
28. [28] Theriault, R.L., Lipton, A., Hortobagyi, G.N., Leff, R., Gluck, S., Stewart, J.F., Costello, S., Kennedy, I., Simeone, J., Seaman, J.J., et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J. Clin. Oncol. 17:3 (1999), 846–854.
29. [29] Kristensen, B., Ejlertsen, B., Groenvold, M., Hein, S., Loft, H., Mouridsen, H.T., Oral clodronate in breast cancer patients with bone metastases: a randomized study. J. Intern. Med. 246:1 (1999), 67–74.
30. [30] Saarto, T., Blomqvist, C., Virkkunen, P., Elomaa, I., Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-Year results of a randomized controlled trial. J. Clin. Oncol. 19:1 (2001), 10–17.
31. [31] Atula, S., Powles, T., Paterson, A., McCloskey, E., Nevalainen, J., Kanis, J., Extended safety profile of oral clodronate after long-term use in primary breast cancer patients. Drug Saf. 26:9 (2003), 661–671.
32. [32] Dearnaley, D.P., Sydes, M.R., Mason, M.D., Stott, M., Powell, C.S., Robinson, A.C.R., Thompson, P.M., Moffat, L.E., Naylor, S.L., Parmar, M.K.B., A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J. Natl. Cancer Inst. 95:17 (2003), 1300–1311.
33. [33] Ernst, D.S., Tannock, I.F., Winquist, E.W., Venner, P.M., Reyno, L., Moore, M.J., Chi, K., Ding, K., Elliott, C., Parulekar, W., Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J. Clin. Oncol. 21:17 (2003), 3335–3342.
34. [34] Campbell, I.A., Douglas, J.G., Francis, R.M., Prescott, R.J., Reid, D.M., Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids. Thorax 59:9 (2004), 761–768.
35. [35] Kraj, M., Poglod, R., Maj, S., Pawlikowski, J., The effects of 8-year pamidronate treatment on skeletal morbidity in patients with advanced multiple myeloma. Nowotwory 54:6 (2004), 570–577.
36. [36] Chesnut, I.C., Skag, A., Christiansen, C., Recker, R., Stakkestad, J.A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R.C., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 19:8 (2004), 1241–1249.
37. [37] Figg, W.D., Liu, Y., Arlen, P., Gulley, J., Steinberg, S.M., Liewehr, D.J., Cox, M.C., Zhai, S., Cremers, S., Parr, A., et al. A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases. J. Urol. 173:3 (2005), 790–796.
38. [38] Attal, M., Harousseau, J.L., Leyvraz, S., Doyen, C., Hulin, C., Benboubker, L., Agha, I.Y., Bourhis, J.H., Garderet, L., Pegourie, B., et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108:10 (2006), 3289–3294.
39. [39] Powles, T., McCroskey, E., Paterson, A., Oral bisphosphonates as adjuvant therapy for operable breast cancer. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 12:20 Pt 2 (2006), 6301s–6304s.
40. [40] Mason, M.D., Sydes, M.R., Glaholm, J., Langley, R.E., Huddart, R.A., Sokal, M., Stott, M., Robinson, A.C., James, N.D., Parmar, M.K., et al. Oral sodium clodronate for nonmetastatic prostate cancer–results of a randomized double-blind placebo-controlled trial: medical Research Council PR04 (ISRCTN61384873). J. Natl. Cancer Inst. 99:10 (2007), 765–776.
41. [41] Diel, L.J., Jaschke, A., Solomayer, E.F., Gollan, C., Bastert, G., Sohn, C., Schuetz, F., Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow - a long-term follow-up. Ann. Oncol. 19:12 (2008), 2007–2011.
42. [42] Kristensen, B., Ejlertsen, B., Mouridsen, H.T., Jensen, M.B., Andersen, J., Bjerregaard, B., Cold, S., Edlund, P., Ewertz, M., Kamby, C., et al. Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol. 47:4 (2008), 740–746.
43. [43] Pandya, K.J., Gajra, A., Warsi, G.M., Argonza-Aviles, E., Ericson, S.G., Wozniak, A.J., Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer. Lung Cancer 67:3 (2010), 330–338.
44. [44] Toussaint, N., Cardiovascular disease and vascular calcification in renal failure. Intern. Med. J., 40, 2010 ((Toussaint N.) Monash Medical Centre, Clayton, Australia):56–57.
45. [45] Paterson, A.H.G., Anderson, S.J., Lembersky, B.C., Fehrenbacher, L., Falkson, C.I., King, K.M., Weir, L.M., Brufsky, A.M., Dakhil, S., Lad, T., et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol. 13:7 (2012), 734–742.
46. [46] Meulenbeld, H.J., Van Werkhoven, E.D., Coenen, J.L.L.M., Creemers, G.J., Loosveld, O.J.L., De Jong, P.C., Ten Tije, A.J., Fossa, S.D., Polee, M., Gerritsen, W., et al. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic castration resistant prostate Cancer (CRPC), the Netherlands prostate study (NePro). Eur. J. Cancer 48:16 (2012), 2993–3000.
47. [47] Banys, M., Solomayer, E.F., Gebauer, G., et al. Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial. BMC Cancer, 13, 2013.
48. [48] Von Minckwitz, G., Rezai, M., Eidtmann, H., Tesch, H., Huober, J., Gerber, B., Zahn, D.M., Costa, S., Gnant, M., Blohmer, J.U., et al. Postneoadjuvant treatment with zoledronate in patients with tumor residuals after anthracyclines-taxane-based chemotherapy for primary breast cancer-The phase III NATAN study (GBG 36/ABCSG XX). Cancer Res., 73(24), 2013.
49. [49] Coleman, R., Cameron, D., Dodwell, D., Bell, R., Wilson, C., Rathbone, E., Keane, M., Gil, M., Burkinshaw, R., Grieve, R., et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol. 15:9 (2014), 997–1006.
50. [50] Denham, J.W., Joseph, D.J., Lamb, D.S., Spry, N., Duchesne, G.M., Matthews, J., Atkinson, C., Tai, K.H., Christie, D., Kenny, L.M., et al. Main oncologic endpoints of the TROG 03.04 (RADAR) Trial for men with locally advanced prostate cancer. J. Clin. Oncol., 32(15), 2014.
51. [51] Gnant, M., Mlineritsch, B., Stoeger, H., Luschin-Ebengreuth, G., Knauer, M., Moik, M., Jakesz, R., Seifert, M., Taucher, S., Bjelic-Radisic, V., et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. ESMO 26:2 (2015), 313–320.
52. [52] Kawahara, T., Nishikawa, M., Kawahara, C., Inazu, T., Sakai, K., Suzuki, G., Atorvastatin, etidronate, or both in patients at high risk for atherosclerotic aortic plaques: a randomized, controlled trial. Circulation 127:23 (2013), 2327–2335.
53. [53] Brincker, H., Westin, J., Abildgaard, N., Gimsing, P., Turesson, I., Hedenus, M., Ford, J., Kandra, A., Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group. Br. J. Haematol. 101:2 (1998), 280–286.
54. [54] Adachi, J.D., Bensen, W.G., Brown, J., Hanley, D., Hodsman, A., Josse, R., Kendler, D.L., Lentle, B., Olszynski, W., Ste-Marie, L.G., et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N. Engl. J. Med. 337:6 (1997), 382–387.
55. [55] Adami, S., Felsenberg, D., Christiansen, C., Robinson, J., Lorenc, R.S., Mahoney, P., Coutant, K., Schimmer, R.C., Delmas, P.D., Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone, 2004, 881–889.
56. [56] Boonen, S., Orwoll, E.S., Wenderoth, D., Stoner, K.J., Eusebio, R., Delmas, P.D., Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J. Bone Miner. Res., 2009, 719–725.
57. [57] Cecilia, D., Jódar, E., Fernández, C., Resines, C., Hawkins, F., Effect of alendronate in elderly patients after low trauma hip fracture repair. Osteoporos. Int., 2009, 903–910.
58. [58] Chailurkit, L.O., Jongjaroenprasert, W., Rungbunnapun, S., Ongphiphadhanakul, B., Sae-tung, S., Rajatanavin, R., Effect of alendronate on bone mineral density and bone turnover in Thai postmenopausal osteoporosis. J. Bone Miner. Metab. 21:6 (2003), 421–427.
59. [59] Chevrel, G., Schott, A.M., Fontanges, E., Charrin, J.E., Lina-Granade, G., Duboeuf, F., Garnero, P., Arlot, M., Raynal, C., Meunier, P.J., Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial. J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 21:2 (2006), 300–306.
60. [60] Conte, P.F., Latreille, J., Mauriac, L., Calabresi, F., Santos, R., Campos, D., Bonneterre, J., Francini, G., Ford, J.M., Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J. Clin. Oncol., 1996, 2552–2559.
61. [61] Cummings, S.R., Black, D.M., Thompson, D.E., Applegate, W.B., Barrett-Connor, E., Musliner, T.A., Palermo, L., Prineas, R., Rubin, S.M., Scott, J.C., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. Jama, 1998, 2077–2082.
62. [62] Dalbeth, N., Aati, O., Gamble, G.D., Horne, A., House, M.E., Roger, M., Doyle, A.J., Chhana, A., McQueen, F.M., Reid, I.R., Zoledronate for prevention of bone erosion in tophaceous gout: a randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis., 2014, 1044–1051.
63. [63] Eastell, R., Nagase, S., Ohyama, M., Small, M., Sawyer, J., Boonen, S., Spector, T., Kuwayama, T., Deacon, S., Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: the OCEAN study. J. Bone Miner. Res., 2011, 1303–1312.
64. [64] Eggelmeijer, F., Papapoulos, S.E., van Paassen, H.C., Dijkmans, B.A., Valkema, R., Westedt, M.L., Landman, J.O., Pauwels, E.K., Breedveld, F.C., Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial. Arthritis Rheum. 39:3 (1996), 396–402.
65. [65] Greenspan, S.L., Resnick, N.M., Parker, R.A., Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. Jama, 2003, 2525–2533.
66. [66] Hines, S.L., Mincey, B.A., Sloan, J.A., Thomas, S.P., Chottiner, E., Loprinzi, C.L., Carlson, M.D., Atherton, P.J., Salim, M., Perez, E.A., Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. J. Clin. Oncol., 2009, 1047–1053.
67. [67] Hosking, D., Chilvers, C.E., Christiansen, C., Ravn, P., Wasnich, R., Ross, P., McClung, M., Balske, A., Thompson, D., Daley, M., et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N. Engl. J. Med., 1998, 485–492.
68. [68] Klotz, L.H., McNeill, I.Y., Kebabdjian, M., Zhang, L., Chin, J.L., A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study. Eur. Urol., 2013, 927–935.
69. [69] Lahtinen, R., Laakso, M., Palva, I., Virkkunen, P., Elomaa, I., Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet (London, England), 1992, 1049–1052.
70. [70] McClung, M.R., Lewiecki, E.M., Cohen, S.B., Bolognese, M.A., Woodson, G.C., Moffett, A.H., Peacock, M., Miller, P.D., Lederman, S.N., Chesnut, C.H., et al. Denosumab in postmenopausal women with low bone mineral density. N. Engl. J. Med., 2006, 821–831.
71. [71] Orwoll, E., Ettinger, M., Weiss, S., Miller, P., Kendler, D., Graham, J., Adami, S., Weber, K., Lorenc, R., Pietschmann, P., et al. Alendronate for the treatment of osteoporosis in men. N. Engl. J. Med., 2000, 604–610.
72. [72] Orwoll, E.S., Binkley, N.C., Lewiecki, E.M., Gruntmanis, U., Fries, M.A., Dasic, G., Efficacy and safety of monthly ibandronate in men with low bone density. Bone, 2010, 970–976.
73. [73] Palomba, S., Manguso, F., Orio, F., Russo, T., Oppedisano, R., Sacchinelli, A., Falbo, A., Tolino, A., Zullo, F., Mastrantonio, P., Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study. Menopause (New York, NY)., 2008, 730–736.
74. [74] Pitt, P., Li, F., Todd, P., Webber, D., Pack, S., Moniz, C., A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term oral corticosteroid treatment. Thorax 53:5 (1998), 351–356.
75. [75] Ravn, P., Clemmesen, B., Riis, B.J., Christiansen, C., The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone, 1996, 527–533.
76. [76] Recker, R., Stakkestad, J.A., Chesnut, C.H., Christiansen, C., Skag, A., Hoiseth, A., Ettinger, M., Mahoney, P., Schimmer, R.C., Delmas, P.D., Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone., 2004, 890–899.
77. [77] Reginster, J.Y., Minne, H.W., Sorensen, O.H., Hooper, M., Roux, C., Brandi, M.L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos. Int., 2000, 83–91.
78. [78] Smerud, K.T., Dolgos, S., Olsen, I.C., Åsberg, A., Sagedal, S., Reisæter, A.V., Midtvedt, K., Pfeffer, P., Ueland, T., Godang, K., et al. A 1-year randomized, double-blind, placebo-controlled study of intravenous ibandronate on bone loss following renal transplantation. Am. J. Transplant., 2012, 3316–3325.
79. [79] Stoch, S.A., Saag, K.G., Greenwald, M., Sebba, A.I., Cohen, S., Verbruggen, N., Giezek, H., West, J., Schnitzer, T.J., Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. J. Rheumatol., 2009, 1705–1714.
80. [80] Tee, S.I., Yosipovitch, G., Chan, Y.C., Chua, S.H., Koh, E.T., Chan, Y.H., Tan, S.S., Tsou, I.Y., Tan, S.H., Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study. Arch. Dermatol., 2012, 307–314.
81. [81] Tripathy, D., Lichinitzer, M., Lazarev, A., MacLachlan, S.A., Apffelstaedt, J., Budde, M., Bergstrom, B., Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann. Oncol., 2004, 743–750.
82. [82] Powles, T., Paterson, A., McCloskey, E., Schein, P., Scheffler, B., Tidy, A., Ashley, S., Smith, I., Ottestad, L., Kanis, J., Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res., 8(2), 2006.
83. [83] Lomashvili, K.A., Monier-Faugere, M.C., Wang, X., Malluche, H.H., O'Neill, W.C., Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. Kidney Int. 75:6 (2009), 617–625.
84. [84] Li, H., Jia, G.L., Wang, H.C., Zhang, R.Q., Tao, H.R., Lu, R., Hu, T., Wang, J., The effect of alendronate on arterial calcification in rat model. Zhonghua nei ke za zhi 45:6 (2006), 489–492.
85. [85] Jackson, B., Gee, A.N., Guyon-Gellin, Y., Niesor, E., Bentzen, C.L., Kerns, W.D., Suckling, K.E., Hypocholesterolaemic and antiatherosclerotic effects of tetra-iso-propyl 2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethyl-1,1-diphosphonate (SR-9223i). Arzneimittel-Forschung 50:4 (2000), 380–386.
86. [86] Li, Q., Sundberg, J.P., Levine, M.A., Terry, S.F., Uitto, J., The effects of bisphosphonates on ectopic soft tissue mineralization caused by mutations in the ABCC6 gene. Cell Cycle 14:7 (2015), 1082–1089.
87. [87] Tanaka, Y., Okada, Y., [Bisphosphonates for vascular calcification]. Clin. Calcium 17:3 (2007), 386–390.
88. [88] McFarlane, S.I., Muniyappa, R., Shin, J.J., Bahtiyar, G., Sowers, J.R., Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link?. Endocrine 23:1 (2004), 1–10.
89. [89] Gonnelli, S., Caffarelli, C., Tanzilli, L., Pondrelli, C., Lucani, B., Franci, B.M., Nuti, R., Effects of intravenous zoledronate and ibandronate on carotid intima-media thickness, lipids and FGF-23 in postmenopausal osteoporotic women. Bone 61 (2014), 27–32.
90. [90] Guney, E., Kisakol, G., Ozgen, A.G., Yilmaz, C., Kabalak, T., Effects of bisphosphonates on lipid metabolism. Neuro Endocrinol. Lett. 29:2 (2008), 252–255.
91. [91] Okamoto, K., Inaba, M., Furumitsu, Y., Ban, A., Mori, N., Yukioka, K., Imanishi, Y., Nishizawa, Y., Beneficial effect of risedronate on arterial thickening and stiffening with a reciprocal relationship to its effect on bone mass in female osteoporosis patients: a longitudinal study. Life Sci. 87:23–26 (2010), 686–691.
92. [92] Celiloglu, M., Aydin, Y., The effect of alendronate sodium on carotid artery intima-media thickness and lipid profile in women with postmenopausal osteoporosis. Maturitas, 63, 2009 ((Celiloglu M.; Aydin Y.) Obstetrics and Gynecology Department, Dokuz Eylul University, Izmir, Turkey):S55.
93. [93] Okamoto, M., Yamanaka, S., Yoshimoto, W., Shigematsu, T., Alendronate as an effective treatment for bone loss and vascular calcification in kidney transplant recipients. J. Transplant., 2014, 2014, 269613.
94. [94] Innasimuthu, A.L., Katz, W.E., Effect of bisphosphonates on the progression of degenerative aortic stenosis. Echocardiography (Mount Kisco, NY) 28:1 (2011), 1–7.
95. [95] Lu, P.Y., Hsieh, C.F., Tsai, Y.W., Huang, W.F., Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate. Clin. Ther. 33:9 (2011), 1173–1179.
96. [96] Kim, D.H., Rogers, J.R., Fulchino, L.A., Kim, C.A., Solomon, D.H., Kim, S.C., Bisphosphonates and risk of cardiovascular events: a meta-analysis. PloS One, 10(4), 2015, e0122646.
97. [97] Igase, M., Kohara, K., Tabara, Y., Ohara, M., Takita, R., Ochi, M., Okada, Y., Miki, T., Change in arterial stiffness associated with monthly bisphosphonate treatment in women with postmenopausal osteoporosis. Menopause (New York, NY) 21:9 (2014), 962–966.
98. [98] Derry, S., Loke, Y.K., Aronson, J.K., Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials. BMC Med. Res. Methodol., 1, 2001, 7.